Provided by Tiger Fintech (Singapore) Pte. Ltd.

Haemonetics

64.80
-0.7200-1.10%
Pre-market: 64.42-0.3800-0.59%05:50 EDT
Volume:1.16M
Turnover:75.10M
Market Cap:3.26B
PE:25.52
High:65.76
Open:65.33
Low:64.35
Close:65.52
Loading ...

Haemonetics Q3 Operating Income USD 59 Million

THOMSON REUTERS
·
02 Mar

Haemonetics Q3 Gross Margin 55.5%

THOMSON REUTERS
·
02 Mar

Haemonetics Q3 Adjusted EPS USD 1.19 VS. Ibes Estimate USD 1.17

THOMSON REUTERS
·
02 Mar

Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now?

Insider Monkey
·
01 Mar

A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q3 Earnings: STAAR Surgical (NASDAQ:STAA) Vs The Rest Of The Pack

StockStory
·
28 Feb

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

Business Wire
·
27 Feb

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

GlobeNewswire
·
27 Feb

US Stocks That May Be Trading At A Discount In February 2025

Simply Wall St.
·
25 Feb

3 US Stocks That May Be Undervalued In February 2025

Simply Wall St.
·
24 Feb

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

Business Wire
·
24 Feb

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

GlobeNewswire
·
24 Feb

Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference

PR Newswire
·
24 Feb

3 US Stocks Estimated To Be Trading Below Their Intrinsic Values

Simply Wall St.
·
24 Feb

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

PR Newswire
·
24 Feb

3 super strong ASX 200 blue chip shares to buy for your SMSF

MotleyFool
·
22 Feb

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

Business Wire
·
21 Feb